If you click on "Accept", you agree to the storage of cookies on your device in order to improve website navigation, analyze website usage and support our marketing efforts.
Read more
Skip to main navigation Skip to content
Novocure
  • about us
  • our therapy
  • our pipeline
  • investor relations
  • careers
  • news and media
  • patient-forward
  • contact us
2021 ESG report
2021 ESG report view 2021 ESG report
  • our story
  • our leadership
  • corporate presentation
  • advocacy
  • ESG
  • external funding
  • our pipeline
  • novocuretrials.com
  • investor relations home
  • stock information
  • corporate presentation
  • SEC filings
  • press releases
  • corporate governance
  • news and media
  • press kit
  • press releases
  • image gallery
  • patient-forward
nasdaq: current stock price
77.25
-1.41
last update 9/29/2022 13:53pm
stock information
These descriptions are editable.
Edit this text by going to Appearance > Menus in the CMS. Then select the Primary Navigation and update the menu items accordingly.
Together with our patients, we strive to extend survival in some of the most aggressive forms of cancer by developing and commercializing our innovative therapy. Learn more about our story, from our founding in Haifa, Israel in 2000 to having grown into a global oncology company today.
Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries.
We join together with patients, caregivers and advocacy partners in their dedication to redefine living with cancer.
Corporate social responsibility is important to us, and patients remain at the heart of the work we do every day.
Novocure is dedicated to supporting independent organizations with shared goals related to advancing medical care and improving patient outcomes.
The science of Tumor Treating Fields extends beyond glioblastoma and mesothelioma. Novocure has ongoing or completed clinical trials investigating our therapy in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Tumor Treating Fields have shown a consistent anti-mitotic effect in our preclinical and clinical research spanning more than two decades.
The science of Tumor Treating Fields extends beyond glioblastoma and mesothelioma. Novocure has ongoing or completed clinical trials investigating our therapy in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
View our press kit, read stories about our company and reach out if you’d like an interview or more information about Novocure.
Stay on top of Novocure news by viewing our latest announcements.
Learn more about our company and our mission through stories about patients, our colleagues, our collaborators and our culture.
learn more
Learn more about our company and our mission through stories about patients, our colleagues, our collaborators and our culture.
Back
  • about us
    • our story
    • our leadership
    • corporate presentation
    • advocacy
    • ESG
    • external funding
  • our therapy
  • our pipeline
    • our pipeline
    • novocuretrials.com
  • investor relations
    • investor relations home
    • stock information
    • corporate presentation
    • SEC filings
    • press releases
    • corporate governance
  • careers
  • news and media
    • news and media
    • press kit
    • press releases
    • image gallery
  • patient-forward
    • patient-forward
  • contact us
visit Novocure Germany
Press Releases

press releases

  • ► 2022
    • September
    • August
    • July
    • June
    • May
    • April
    • March
    • February
    • January
  • ► 2021
    • December
    • November
    • October
    • September
    • July
    • June
    • May
    • April
    • February
    • January
  • ► 2020
    • December
    • November
    • October
    • September
    • August
    • July
    • June
    • May
    • April
    • March
    • February
    • January
  • ► 2019
    • December
    • November
    • October
    • September
    • August
    • July
    • June
    • May
    • April
    • March
    • February
    • January
  • ► 2018
    • December
    • November
    • October
    • September
    • August
    • July
    • June
    • May
    • April
    • March
    • February
    • January
  • ► 2017
    • December
    • November
    • October
    • September
    • August
    • July
    • June
    • May
    • April
    • March
    • February
    • January
  • ► 2016
    • December
    • November
    • October
    • September
    • August
    • July
    • June
    • May
    • April
    • March
    • February
    • January
  • ► 2015
    • December
    • November
    • October
    • September
    • August
    • July
    • May
    • April
    • March
    • February
    • January
  • ► 2014
    • December
    • November
    • October
    • September
    • August
    • July
    • June
    • May
    • April
    • February
    • January
  • ► 2013
    • December
    • November
    • August
    • July
    • May
    • January
  • ► 2012
    • November
    • August
    • May
    • January
  • ► 2011
    • December
    • November
    • October
    • August
    • April
    • March
  • ► 2010
    • October
    • June
  • ► 2009
    • September
  • ► 2008
    • November
    • April
  • ► 2007
    • March
September 25, 2014

Novocure™ Announces Recurrent Glioblastoma Patient Registry Dataset (PRiDe) to be Presented at ESMO and EANO 2014

learn more
September 25, 2014

Novocure™ Announces Recurrent Glioblastoma Patient Registry Dataset (PRiDe) to be Presented at ESMO and EANO 2014

learn more
September 25, 2014

Novocure™ Announces Recurrent Glioblastoma Patient Registry Dataset (PRiDe) to be Presented at ESMO and EANO 2014

learn more
September 4, 2014

NovoTTF™-100A System Granted High Unmet Medical Need Designation by the Japanese Ministry of Health and Welfare

learn more
September 4, 2014

NovoTTF™-100A System Granted High Unmet Medical Need Designation by the Japanese Ministry of Health and Welfare

learn more
September 4, 2014

NovoTTF™-100A System Granted High Unmet Medical Need Designation by the Japanese Ministry of Health and Welfare

learn more
about us
our story
our leadership
corporate presentation
advocacy
ESG
external funding
our therapy
our pipeline
our pipeline
novocuretrials.com
investor relations
investor relations home
stock information
corporate presentation
SEC filings
press releases
corporate governance
careers
news and media
news and media
press kit
press releases
image gallery
patient-forward
patient-forward
Additional Information
corporate compliance california consumer privacy notice privacy notice hipaa privacy notice terms and conditions site map novocure vulnerability disclosure process

On this site, videos and images identified as Optune users, caregivers or healthcare professionals depict actual patients, caregivers and healthcare professionals. Patient images reflect the health status of the patients at the time each photo or video was taken.

© 2022 Novocure GmbH all rights reserved

Novocure

© 2022 Novocure GmbH all rights reserved

​
Close Modal
​

Are you sure you'd like to continue?

This link will navigate you to an external website outside of Novocure.com.

Cancel Continue